Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T2023-004 Phase 2 Trial of Revumenib (SNDX-5613) in Combination With FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged Acute Myeloid Leukemia

NCT07686107 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT07686107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07686107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T2023-004 Phase 2 Trial of Revumenib (SNDX-5613) in Combination With FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged Acute Myeloid Leukemia
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2030
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute